Taxifolin prevents β-amyloid-induced impairments of synaptic formation and deficits of memory via the inhibition of cytosolic phospholipase A2/prostaglandin E2 content
- 8 Downloads
Taxifolin is a potent flavonoid with anti-inflammatory activity. Taxifolin has been reported to decrease the accumulation of β-amyloid (Aβ), and reduce Aβ-induced neurotoxicity. However, the detail molecular mechanism of taxifolin against Aβ-induced neurotoxicity is largely unknown. In this study, we revealed the protective effects and the underlying mechanisms of taxifolin on the impairments of cognitive function and synapse formation induced by soluble Aβ oligomers. Our results showed that taxifolin prevented neuronal cell death in a concentration-dependent manner. The recognition memory in novel object recognition tasks and the spatial memory in Morris water maze tests are significantly lower in the Alzheimer’s disease (AD) model mice induced by hippocampal injection of Aβ42. Taxifolin treatment prevented the recognitive and spatial memory deficits of the AD mice. 10 mg/kg taxifolin treatment also significantly prevented the decreased expression levels of PSD 95 induced by Aβ42. Live cell imaging study showed that 2 h pre-treatment of taxifolin prevented the decrease in the number of filopodium and spine induced by Aβ42 oligomers. Aβ42 oligomers significantly increased the production of cytosolic phospholipase A2 (cPLA2), a crucial enzyme of pro-inflammatory mediator, and prostaglandin E2 (PGE2), a neuroinflammatory molecule. Taxifolin significantly reduced the content of cPLA2 and PGE2 induced by Aβ42 both in the primary hippocampal neurons and hippocampal tissues. These results indicated that taxifolin might prevent Aβ42 oligomer-induced synapse and cognitive impairments through decreasing cPLA2 and PGE2. Our study provided novel insights into the cellular mechanisms for the protective effects of taxifolin on AD.
KeywordsTaxifolin Alzheimer’s disease Cognitive impairments Synapse Prostaglandin E2 Cytosolic phospholipase A2
- SO Aβ
Soluble oligomers of Aβ
Cytosolic phospholipase A2
This work was supported by grants from The National Natural Science Foundation of China (81771166 and 81471398), Natural Science Foundation of Zhejiang Province (LY16H090001 and LY14H090004), Natural Science Foundation of Ningbo (2015A610211), Ningbo municipal innovation team of life science and health (2015C110026), and the K.C.Wong Magna Fund in Ningbo University.
Compliance with ethical standards
Conflict of interest
The authors have no conflicts of interest.
- Arbel-Ornath M, Hudry E, Boivin JR, Hashimoto T, Takeda S, Kuchibhotla KV, Hou S, Lattarulo CR, Belcher AM, Shakerdge N, Trujillo PB, Muzikansky A, Betensky RA, Hyman BT, Bacskai BJ (2017) Soluble oligomeric amyloid-beta induces calcium dyshomeostasis that precedes synapse loss in the living mouse brain. Mol Neurodegener 12:27–40CrossRefPubMedPubMedCentralGoogle Scholar
- Bate C, Williams A (2015a) Alpha-Synuclein-induced synapse damage in cultured neurons is mediated by cholesterol-sensitive activation of cytoplasmic phospholipase A2. Biomol Ther 5:178–193Google Scholar
- Bate C, Williams A (2015b) cAMP-inhibits cytoplasmic phospholipase a(2) and protects neurons against amyloid-beta-induced synapse damage. Biol (Basel) 4:591–606Google Scholar
- Brummett AM, Navratil AR, Bryan JD, Woolard MD (2014) Janus kinase 3 activity is necessary for phosphorylation of cytosolic phospholipase A2 and prostaglandin E2 synthesis by macrophages infected with Francisella tularensis live vaccine strain. Infect Immun 82:970–982CrossRefPubMedPubMedCentralGoogle Scholar
- Hermann PM, Watson SN, Wildering WC (2014) Phospholipase A2 - nexus of aging, oxidative stress, neuronal excitability, and functional decline of the aging nervous system? Insights from a snail model system of neuronal aging and age-associated memory impairment. Front Genet 5:1–18CrossRefGoogle Scholar
- Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ, Castellani RJ, Crain BJ, Davies P, Del Tredici K, Duyckaerts C, Frosch MP, Haroutunian V, Hof PR, Hulette CM, Hyman BT, Iwatsubo T, Jellinger KA, Jicha GA, Kovari E, Kukull WA, Leverenz JB, Love S, Mackenzie IR, Mann DM, Masliah E, McKee AC, Montine TJ, Morris JC, Schneider JA, Sonnen JA, Thal DR, Trojanowski JQ, Troncoso JC, Wisniewski T, Woltjer RL, Beach TG (2012) Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol 71:362–381CrossRefPubMedPubMedCentralGoogle Scholar
- Park SY, Kim HY, Park HJ, Shin HK, Hong KW, Kim CD (2016) Concurrent treatment with Taxifolin and Cilostazol on the lowering of beta-amyloid accumulation and neurotoxicity via the suppression of P-JAK2/P-STAT3/NF-kappaB/BACE1 signaling pathways. PLoS One 11:e0168286CrossRefPubMedPubMedCentralGoogle Scholar
- Saito S, Yamamoto Y, Maki T, Hattori Y, Ito H, Mizuno K, Harada-Shiba M, Kalaria RN, Fukushima M, Takahashi R, Ihara M (2017) Taxifolin inhibits amyloid-beta oligomer formation and fully restores vascular integrity and memory in cerebral amyloid angiopathy. Acta Neuropathol Commun 5:26CrossRefPubMedPubMedCentralGoogle Scholar
- Wang Q, Walsh DM, Rowan MJ, Selkoe DJ, Anwyl R (2004) Block of long-term potentiation by naturally secreted and synthetic amyloid beta-peptide in hippocampal slices is mediated via activation of the kinases c-Jun N-terminal kinase, cyclin-dependent kinase 5, and p38 mitogen-activated protein kinase as well as metabotropic glutamate receptor type 5. J Neurosci 24:3370–3378CrossRefPubMedGoogle Scholar
- Yang P, Xu F, Li HF, Wang Y, Li FC, Shang MY, Liu GX, Wang X, Cai SQ (2016) Detection of 191 Taxifolin metabolites and their distribution in rats using HPLC-ESI-IT-TOF-MS(n). Molecules 21:1209–1234Google Scholar